Stock Performance and Downgrade Analysis
Shares of Hims & Hers Health Inc (NYSE:HIMS) experienced a notable decline following a downgrade by Citigroup (NYSE:C), which classified the stock as Sell/High Risk. This downgrade is primarily centered around perceived overvaluation issues regarding its GLP-1 revenue stream.
Amid premarket trading, the stock noted a decline exceeding 3%, prompting investor concerns and market speculation.
Risks Associated with GLP-1 Revenue Stream
Citi's report outlined significant risks impacting the company's revenue generation, especially within the weight-loss segment where changing regulations and evolving market dynamics could hinder growth. Analysts emphasized the potential decrease in HIMS’ GLP-1 revenues, projecting a drop from $400 million anticipated in fiscal year 2025 to just $135 million.
This outlook stems from the FDA's recent action to remove Tirzepatide from the drug shortage list, which limits the bulk compounding of GLP-1 formulations under the 503A exemption. Such regulatory shifts pose a substantial challenge to HIMS' operational strategies.
Future Implications of Regulatory Changes
The report raises concerns about a similar regulatory decision regarding Semaglutide, anticipated to occur within the next year. Such changes could further restrict HIMS' capabilities to provide compounded GLP-1 treatments effectively.
Analysts from Citi stated, “With Tirzepatide now officially removed from the shortage list, we believe it's more probable that Semaglutide could follow suit in the next 12 months.” If this transpires, it would significantly limit HIMS’ position in the weight-loss market, confining their ability to compound GLP-1s to specific clinical benefits for individual patients.
Competitive Landscape and Market Challenges
Adding to HIMS’ challenges is the ever-increasing competition in the direct-to-consumer healthcare sector. Major pharmaceutical companies, established platforms, and technology giants are expanding their presence in this market, leading to higher customer turnover rates, pricing pressures, and escalating customer acquisition costs for companies like HIMS.
This competitive landscape could dilute HIMS’ strength outside its GLP-1 revenue and exert additional strain on its financial outcomes.
Valuation Concerns and Projections
From a valuation perspective, analysts from Citi highlighted that HIMS is trading at an enterprise value-to-EBITDA multiple of 18.7x for the calendar year 2026, outpacing its industry peers. Despite the mounting risks, this high valuation does not seem to accommodate the anticipated obstacles that lie ahead, including regulatory uncertainties and an increasingly competitive environment.
Hims & Hers’ weight-loss product offerings remain a crucial consideration for 2025, especially as regulatory stances towards Semaglutide shortages evolve. While a removal from the shortage list is deemed less likely, some regulatory adjustments are expected.
Long-term Revenue Expectations
Even amidst these hurdles, Citi remains cognizant of HIMS’ initiatives to bolster its weight-loss business model. For the year 2025, continued revenue growth is projected at 47%, led by a remarkable 170% increase in GLP-1 revenue targeting the $400 million mark. Simultaneously, a growth approximation of 30% in non-GLP-1 revenue is anticipated.
Nevertheless, analysts forecast that the shift towards lower-margin GLP-1s, coupled with intensifying competition, might compress gross margins by 90 basis points. However, this could be partially mitigated by an estimated 130 basis points of adjusted EBITDA margin enhancement attributed to operational expense leverage.
Frequently Asked Questions
What triggered the decline in Hims & Hers Health's stock?
The decline was prompted by a downgrade from Citigroup, which cited overvaluation concerns associated with its GLP-1 revenue stream.
How significant is the projected drop in GLP-1 revenues for Hims & Hers?
Citi analysts project a decrease from $400 million to $135 million for fiscal year 2025 due to regulatory changes affecting GLP-1 treatments.
What implications does the FDA's decision hold for Hims & Hers’ business model?
The FDA's removal of Tirzepatide from the drug shortage list limits Hims & Hers' ability to compound GLP-1s, posing challenges to their weight-loss offerings.
Are there competitive threats facing Hims & Hers?
Yes, the direct-to-consumer healthcare market is witnessing increased competition from pharmaceutical and tech companies, leading to pricing pressure and higher customer acquisition costs.
What are the revenue forecasts for Hims & Hers in the coming years?
Forecasts project a 47% revenue growth for 2025, driven by GLP-1 revenues despite potential margin compressions due to market dynamics and competition.
